UK OKAYS EARLY USE OF NOVARTIS BREAST CANCER DRUG

A A

Novartis AG has won approval for its drug Femara to be used in a wider range of British women with breast cancer, the Swiss company said on Thursday. Britain's Medicines and Healthcare Products Regulatory Agency cleared the medicine for treatment after surgery of postmenopausal women who have hormone-positive early invasive breast cancer. The licence approval is ahead of the rest of Europe and the United States, and follows a similar green light for AstraZeneca Plc's rival product, Arimidex, in June.

Scotsman (http://business.scotsman.com/latest.cfm?id=2369412005)